Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

We aim to publish our findings in leading peer-reviewed journals. Follow this page for updates.

Patent for non-invasive prenatal diagnosis of autosomal recessive disorders.

SCHUH A. and Henderson S.

Clinical-grade validation of whole genome sequencing reveals robust detection of low-frequency variants and copy number alterations in CLL

Klintman J. et al, British Journal of Haematology

Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis.

Kaisaki PJ. et al, (2016), PLoS One, 11

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.

Campo E. et al, (2018), Haematologica, 103, 1956 - 1968

Linking genotype to clinical phenotype through proteomic analysis of CLL trial samples

Eagle G. et al, (2017), LEUKEMIA & LYMPHOMA, 58, 100 - 101

The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory CLL shows acceptable safety and promising early indications of efficacy

Munoz-Vicente S. et al, (2017), LEUKEMIA & LYMPHOMA, 58, 239 - 239

Patients' Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment.

Buchanan J. et al, (2016), Patient, 9, 525 - 536

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.

Fernandez-Mercado M. et al, (2013), Haematologica, 98, 1856 - 1864

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.

Oscier D. et al, (2012), Br J Haematol, 159, 541 - 564

Screening for clinically significant non-deletional alpha thalassaemia mutations by pyrosequencing.

Haywood A. et al, (2010), Ann Hematol, 89, 1215 - 1221

Incidence of haemoglobinopathies in various populations - the impact of immigration.

Henderson S. et al, (2009), Clin Biochem, 42, 1745 - 1756

ETO-2 associates with SCL in erythroid cells and megakaryocytes and provides repressor functions in erythropoiesis.

Schuh AH. et al, (2005), Mol Cell Biol, 25, 10235 - 10250

Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.

Chanan-Khan AA. et al, (2017), Lancet Haematol, 4, e534 - e543

Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.

Howard DR. et al, (2017), Leukemia, 31, 2416 - 2425

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.

Parker H. et al, (2016), Leukemia, 30, 2179 - 2186

Progressive multifocal leukoencephalopathy as the presenting feature of chronic lymphocytic leukaemia.

Bruce DR. et al, (2014), Br J Haematol, 167, 570 - 571

Issues surrounding the health economic evaluation of genomic technologies.

Buchanan J. et al, (2013), Pharmacogenomics, 14, 1833 - 1847

Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme.

Chowdhury O. et al, (2011), Br J Haematol, 155, 519 - 521

Quantitation of leukemic stem cell populations predicts clinical outcome in Acute Myeloid Leukaemia

Craddock CF. et al, (2011), Blood -New York-, 118, 292 - 292

MicroRNA expression in chronic lymphocytic leukaemia.

Lawrie CH. et al, (2009), Br J Haematol, 147, 398 - 402

Load More

1
2
3
4
5
6
7
...
»